FDA follows experts' advice and blocks Capricor DMD therapy

News
FDA follows experts' advice and blocks Capricor DMD therapy

The FDA has dashed Capricor Therapeutics' hope of getting approval for its cell therapy for Duchenne muscular dystrophy (DMD).

The US regulator has sent a complete response letter (CRL) to the San Diego-based biotech for deramiocel, following the lead of its Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC), which voted nine to three in July that the data submitted in the marketing application did not provide "substantial evidence" of efficacy.

News of the rejection on Friday came too late to affect Capricor's share price before the Nasdaq closed, but the stock was pummelled in after-hours trading, losing nearly 80% of its value.

The company has scheduled a conference call tomorrow (Monday 23rd) to update shareholders on its plans. It ended the third quarter with just under $199 million in cash, enough to fund about a year of operations, and now says it will look at ways to reduce operating costs to extend that runway.

The CRL said that the FDA "does not consider the data sufficient to establish substantial evidence of effectiveness," along with other clinical deficiencies, according to a company statement.

Deramiocel – which is based on donor cardiosphere-derived cells (CDCs) given by intravenous infusion – is designed to release cellular factors that dampen down inflammation and slow down the skeletal, respiratory, and cardiac muscle degeneration seen in people living with DMD. Over time, deterioration of the heart muscle leads to cardiomyopathy and heart failure, which is the leading cause of death in DMD.

The cell therapy was turned down by the FDA last year as a treatment for cardiomyopathy associated with DMD, but was subsequently refiled as a treatment for skeletal and cardiac manifestations of the muscle-wasting disease.

"We are deeply disappointed for the boys and young men living with Duchenne and their families,” said Linda Marbán, Capricor's chief executive.

"Deramiocel has been studied in two randomised, double-blind, placebo-controlled trials, HOPE-2 and HOPE-3, both of which met their primary endpoints. We stand behind the rigour of our clinical program and the integrity of our data, and we believe the data support approval," she added.

At the advisory committee meeting, panellists said they were concerned that Capricor had changed the endpoints in the main HOPE-3 trial, saying it made the results harder to interpret.

Specifically, they cited the change in the measurement of heart-pumping capacity from direct changes in blood volume pumped per beat to a rank-based system of patient results. Similarly, upper limb function was calculated as a percentage change, rather than sticking to the original protocol of scores generated by a 42-point functional test.

"We are reviewing the letter carefully and will share next steps once we have completed our evaluation," said Marbán.